Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Market Cap	90.55M
Revenue (ttm)	n/a
Net Income (ttm)	-50.29M
Shares Out	12.24M
EPS (ttm)	-4.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,575
Open	7.36
Previous Close	7.54
Day's Range	7.28 - 7.57
52-Week Range	4.64 - 61.90
Beta	3.20
Analysts	Strong Buy
Price Target	53.56 (+623.78%)
Earnings Date	May 6, 2025

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBP
• Website: https://www.corbuspharma.com

Analyst Forecast

According to 10 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price forecast is $53.56, which is an increase of 623.78% from the latest price.

Price Target

$53.56

(623.78% upside)

Analyst Consensus: Strong Buy